Samsung BioLogics has signed an additional contract manufacturing organization (CMO) deal with the global pharmaceutical company UCB.
Samsung BioLogics said on Aug. 2 that it has signed a CMO deal with UCB to curb the accumulation of tau protein, known as a key factor in the outbreak of central nervous system disease and Alzheimer's.
Samsung BioLogics has signed a contract with UCB for consignment production for the third time. This is the third CMO contract with UCB, only 17 months after the first and second contracts were signed in December 2017.
UCB is considered a global top-tier pharmaceutical company that achieved 4.6 billion euros (about 6 trillion won) in sales in 2018 while playing a leading role in the development of new drugs in neurology and immunology. Signing three production contracts with UCB in a short period of time is considered a highly unusual achievement.
The success or failure largely depends on pharmaceutical companies' selection of bio-medicine development and production partners as they are directly linked with their own credibility.
Samsung BioLogics CEO Kim Tae-han said, "We will do our best to support the early commercialization of the new UCB drug by utilizing the latest facilities of the plant 3."